The case for a value-based formulary: striving for total lowest net cost

Manag Care Interface. 2007 Apr;20(4):42-7.

Abstract

A value-based formulary, supported by a full-disclosure financial model, ensures the use of the most appropriate drugs at the lowest net cost. It is a complex process that requires a high level of ongoing due diligence by the Pharmacy & Therapeutics Committee responsible for managing an organization's formularies. Choosing the appropriate drugs for a formulary goes beyond safety, efficacy, and pricing. These are important factors, but determining the appropriateness of a drug also involves demographic considerations, compliance probabilities, and a comparison of desired medical outcomes.

MeSH terms

  • Cost-Benefit Analysis
  • Decision Making, Organizational
  • Disease Management*
  • Drug Costs
  • Drug Interactions
  • Evidence-Based Medicine*
  • Formularies as Topic / standards*
  • Humans
  • Managed Care Programs / economics*
  • Managed Care Programs / standards
  • Pharmaceutical Services / economics*
  • Pharmaceutical Services / standards
  • Pharmacy and Therapeutics Committee*
  • Quality Assurance, Health Care
  • United States